COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376805
Recruitment Status : Terminated (Withdrawn due to toxicity)
First Posted : September 15, 2006
Results First Posted : August 12, 2010
Last Update Posted : December 28, 2017
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:

RATIONALE: Giving chemotherapy before a donor natural killer (NK) cell infusion helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's cells. Giving NK cells from a related donor may kill the tumor cells.

PURPOSE: This study furthers the research of previous studies (MT2003-01 and MT2004-25) which were to determine a specific preparatory regimen (cyclophosphamide and fludarabine) could create an environment in which infused NK cells can grow and effectively treat patients with relapsed AML. This study will test the previous regimen in patients with breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Fludarabine Drug: Cyclophosphamide Radiation: Total body irradiation Other: Natural killer cell infusion Biological: Interleukin-2 Phase 2

Detailed Description:
We believe that administration of related allogeneic (donor) natural killer cells along with IL-2, rather than autologous natural killer cells will provide the most effective anticancer therapy in this setting, and wish to test this approach. To do this, we will select a related donor who is partially HLA-matched with the study subject, to increase the likelihood that donor natural killer cells will kill the subject's cancer cells. We will also give chemotherapy drugs to increase the subject's tolerance for the donor natural killer cells. We will test the use of donor natural killer (NK) cell infusions. The immune system has a special way that it sees and identifies cancer cells or foreign agents (like viruses). The subject's own NK cells may not attack their cancer because NK cells see the tumor cells as "self" (a coating on the cell surface identifies a cell as "self" or "non-self"). We have reason to believe that NK cells may not kill cancer cells because NK cells have special receptors that "turn them off" when they encounter cancer cells (by seeing them as "self"). We may be able to get around this problem by using donor NK cells. Finally, subjects will receive a dose of subcutaneous IL-2 3 times a week (for 2 weeks) which has been proven safe in our previous studies to stimulate the natural killer cells.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer
Study Start Date : April 2006
Actual Primary Completion Date : September 2009
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: All Treated Patients
All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
Drug: Fludarabine
administered intravenously 25 mg/m^2 times 5 doses
Other Name: Fludara

Drug: Cyclophosphamide
administered intravenously 60 mg/kg days times 2 doses.
Other Name: Endoxan, Cytoxan, Neosar, Procytox

Radiation: Total body irradiation
200 cGy (gray) on day -1
Other Name: radiation

Other: Natural killer cell infusion
Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
Other Name: NK cells

Biological: Interleukin-2
administered subcutaneously (10 MU) 3 times per week for 6 doses
Other Name: IL-2

Primary Outcome Measures :
  1. Number of Patients Who Had Expansion of Natural Killer Cells [ Time Frame: Day 14 ]
    Successful Natural Killer (NK) cell expansion is defined as detection of an absolute circulating donor-derived NK cell count of >100 cells/ul of whole blood 14 days after infusion with <5% donor T and B cells in mononuclear population (in metastatic breast cancer patients).

Secondary Outcome Measures :
  1. Number of Patients by Disease Response [ Time Frame: 6 Months, 1 Year ]

    Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria:

    • Complete Response (CR: Disappearance of all target lesions
    • Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
    • Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD
    • Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions of appearance of one or more new lesions

    of clinical benefit (CB; stable disease for greater than 6 months.

  2. Number of Patients Who Died While on Study [ Time Frame: Within 100 days, After 100 days ]
    Number of patients who died within 100 days and after 100 days of natural killer (NK) treatment with or without total body irradiation.

  3. Overall Median Number of Days Patients Alive After Treatment [ Time Frame: First Day of Treatment Until Death ]
    Calculated median number of days of survival (patients alive days after treatment).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Diagnosis of metastatic breast cancer that has progressed on or failed at least one salvage chemotherapy regimen for metastatic disease and that meets the following disease specific related criteria:

    • Measureable metastatic disease per Response Evaluation Criteria In Solid Tumor (RECIST) - bone only not eligible.
    • Disease progression while receiving prior therapy with a hormonal agent (if estrogen/progesterone receptor-positive) and/or trastuzumab (Herceptin®) (if HER2-neu positive)
    • Brain metastases allowed provided they are stable for ≥ 3 months after prior treatment
  • Related HLA-haploidentical natural killer cell donor available (by ≥ class I serologic typing)
  • Male or female
  • Performance status 50-100%
  • Platelet count ≥ 80,000/mm³ (unsupported by transfusions)
  • Hemoglobin ≥ 9 g/dL (unsupported by transfusions)
  • Absolute neutrophil count ≥ 1,000/mm³ (unsupported by sargramostim [GM-CSF] or filgrastim [G-CSF])
  • Creatinine ≤ 2.0 mg/dL
  • Liver function tests < 5 times normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • LVEF > 40%*
  • Pulmonary function > 50%* (DLCO corrected AND FEV_1)
  • No active infection (i.e., afebrile, off antibiotics, and no uninvestigated radiologic lesions)

Exclusion Criteria:

  • At least 3 days since prior prednisone or other immunosuppressive medications
  • No other concurrent therapy for cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376805

Layout table for location information
United States, Minnesota
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Layout table for investigator information
Study Chair: Jeffrey Miller, MD Masonic Cancer Center, University of Minnesota
Principal Investigator: Sarah Cooley, MD Masonic Cancer Center, University of Minnesota
Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota Identifier: NCT00376805    
Obsolete Identifiers: NCT00167193
Other Study ID Numbers: UMN-2005LS033
UMN-0505M70037 ( Other Identifier: IRB, University of Minnesota )
UMN-MT2005-08 ( Other Identifier: Blood and Bone Marrow Transplantation Program )
First Posted: September 15, 2006    Key Record Dates
Results First Posted: August 12, 2010
Last Update Posted: December 28, 2017
Last Verified: December 2017
Keywords provided by Masonic Cancer Center, University of Minnesota:
stage IV breast cancer
male breast cancer
recurrent breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents